Literature DB >> 7605884

Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls.

D Hagger1, S Wolff, J Owen, D Samson.   

Abstract

Seventeen parameters of coagulation and fibrinolysis were measured in 33 patients with sickle cell disease; 30 were tested in steady state (SS) and 19 in crisis (Cr). There were 16 patients in both groups. The same parameters were measured in 16 controls of similar ethnic origin (Black controls; BC) and 20 Caucasian controls (CC), all with HbA only. Highly significant differences (P < 0.001) between Black and Caucasian control groups were noted for: fibrinogen, fibrinopeptide-A (FPA), beta-thromboglobulin (beta TG) and D-dimer. Significant differences (P < 0.03) in plasminogen activator inhibitor (PAI) and functional antithrombin III levels were also noted. Results of the sickle cell patients were therefore compared with those of the Black controls. Sickle cell patients in SS had raised v Wf compared with BC, which increased further during Cr (P = 0.001), but showed no significant increase in fibrinogen. Functional protein C was reduced in SS (P = 0.004) but with no further fall in Cr, while free protein S was normal in SS but reduced in Cr (P = 0.02). Total protein S and ATIII were normal in SS and Cr. FPA and beta TG were not significantly raised in SS or Cr compared with BC. There were, however, highly significant increases in D-dimer and thrombin-antithrombin complexes (TAT) in both SS and Cr compared with BC (P < 0.001 for SS and Cr vs BC). Thus significant activation of coagulation with consequent increase in fibrinolysis occurs during both the sickle cell crisis and in the steady state.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7605884     DOI: 10.1097/00001721-199504000-00001

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  20 in total

1.  Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.

Authors:  Roberto F Machado; Mark T Gladwin
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

2.  Elevated D-dimer levels in African Americans with sickle cell trait.

Authors:  Rakhi P Naik; James G Wilson; Lynette Ekunwe; Stanford Mwasongwe; Qing Duan; Yun Li; Adolfo Correa; Alexander P Reiner
Journal:  Blood       Date:  2016-03-11       Impact factor: 22.113

3.  Developing new pharmacotherapeutic approaches to treating sickle-cell disease.

Authors:  Marilyn J Telen
Journal:  ISBT Sci Ser       Date:  2016-11-15

4.  Role of the coagulation system in the pathogenesis of sickle cell disease.

Authors:  Md Nasimuzzaman; Punam Malik
Journal:  Blood Adv       Date:  2019-10-22

Review 5.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

6.  Raised D-dimer levels in acute sickle cell crisis and their correlation with chest X-ray abnormalities.

Authors:  Javeed Dar; Inam Mughal; Hilali Hassan; Taj E Al Mekki; Zivani Chapunduka; Imad S A Hassan
Journal:  Ger Med Sci       Date:  2010-10-08

Review 7.  How I diagnose and treat venous thromboembolism in sickle cell disease.

Authors:  Arun S Shet; Ted Wun
Journal:  Blood       Date:  2018-05-15       Impact factor: 22.113

8.  Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia.

Authors:  Suba Krishnan; Jamie Siegel; Gene Pullen; Megan Hevelow; Carlton Dampier; Marie Stuart
Journal:  Thromb Res       Date:  2008-01-29       Impact factor: 3.944

Review 9.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

Review 10.  Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.

Authors:  Roberto F Machado; Harrison W Farber
Journal:  Clin Chest Med       Date:  2013-10-17       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.